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Advances in molecular medicine offer the potential to move cancer
therapy beyond traditional cytotoxic treatments to safer and more
effective targeted therapies based on molecular characteristics of a
patient’s tumor. Within this context, the role of quantitative imaging
as an in vivo biomarker has received considerable attention as a means
to predict and measure the response to therapy. For example, the ability
to predict the response to therapy quantitatively, early in the drug or
radiation therapy regime, would facilitate adaptive therapy trial strate-
gies, that is, that permit alternative treatment regimens in cases where
initial therapy response was ineffective. Similarly, the ability to measure
the response to therapy should provide a more robust means for both
therapy dose management and correlation of imaging results with
other laboratory biomarkers. The latter is required for clinical decision
making in the clinical setting. The National Cancer Institute (NCI)
in collaboration with the Food and Drug Administration (FDA) has
therefore promoted a number of initiatives supporting the role of
molecular imaging in drug trials. The major goal of these initiatives
is the “qualification” of the proposed molecular imaging protocol(s) that
can be incorporated into current or future drug trials submitted to the
FDA. Clinical research strategies that will help achieve these goals are
described in the published literature [1–5].
The physical uncertainty in the measurement of response to therapy
as applied to biomarker trials is also important because it may negatively
influence the ability to detect an early response. While we expect bio-
logic variability in the response rate of individuals, we also expect the
physical uncertainty resulting from data collection and analysis methods
to be quantified such that we can power a trial to detect a given bio-
logic effect size across individuals. Such sources of error are often depen-
dent on the selected imaging platform and imaging protocol. As a result,
there is a critical a priori need to characterize the physical measurement
uncertainty across different commercial imaging platforms before the
implementation of multisite, multiplatform clinical trials. This charac-
terization is necessary to determine the level of random (noise) and
systematic (bias) error in themeasurement system that impacts themini-
mum change that can be measured. In other words, if we use appro-
priate, quality-controlled imaging platforms and optimal low-noise,
unbiased data analysis methods, physical measurement uncertainty
can be decreased, thus allowing the required number of individuals
used in trials to be decreased while maintaining the same power to
detect a given biologic response. This information is especially critical
if imaging is to be used to support adaptive trial designs. In addition,
it may be possible, depending on the commercial imaging platforms
involved and clinical protocol, to harmonize data collection and analysis
across the different imaging platforms used in multicenter clinical trials,
reducing, for example, the uncertainty in data correlation with other
laboratory biomarkers, as required for clinical decision making [6–9].
NCI is currently addressing the physical measurement uncertainty
problem for imaging as a biomarker using several synergistic and com-
plementary initiatives. The goal is to engage all of the important stake-
holders in the imaging field (academia, imaging and pharmaceutical
industries, scientific imaging societies, and the different agencies of
the federal government) to first explore the development of a broad
consensus on how to develop quantitative imaging methods and then
to encourage the adoption of more standardized methods for quality
assurance and quantitative imaging by the academic and industry com-
munities as a long-term goal. These initiatives include the following:
1. Reference Image Database to Evaluate Response to Therapy
(RIDER): The RIDER project, established as a pilot project
in 2005, refers to the development of Web-accessible public
resources of image data, designed to permit the comparison
of different imaging and analysis methods for the measurement
of therapy response, archived on the NCI imaging archive, de-
scribed below [10,11].
2. CaBIG ImagingWorkspace andNCI ImageArchive: The goal of
this initiative, supported by NCI caBIG, is to develop an open
computer architecture that supports interoperability of database
and software tools and to provide a comprehensive image archive
to store and query these data, meeting all DICOM and caBIG
requirements. A secondary goal is to permit an environment
where plug and play software tools can be used to help develop
common approaches for data collection and analysis, thus sup-
porting quantitative imaging standards for imaging as a bio-
marker [12,13]
3. Quantitative Imaging Network (QIN found in PAR-08-225):
The QIN project was recently published in 2008 as a program
announcement. The goal of this initiative is to support multi-
disciplinary research teams to develop quantitative imaging
methods to measure the response to therapy, using current com-
mercial imaging platforms. The teams will then optimize the per-
formance of their quantitative imaging tools within ongoing
phase 1 to 3 clinical therapy trials. A secondary goal is to provide
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the image, meta data, clinical outcome data, and measurement
results as a public resource using the NCI image archive [14].
4. Network for Translational Research (NTR found in RFA-CA-
08-002): The goal of NTR is to develop, validate, and translate
the next generation of multimodality and molecular imaging
platforms for targeted cancer problems. Although the NTR
goals are not specifically directed at the role of imaging as a bio-
marker, the research goals include the harmonization and stan-
dardization of quantitative imaging methods that may serve as
a combined platform to detect, diagnose, and treat cancer. The
NTR is also tasked to support image data sharing as a public
resource using the NCI image archive [15]
5. Academic Industry Partnerships for Translational Research
(R01: PAR-07-214). The goal of this program announcement
is the support of academic and industry partnerships directed at
translational research and to encourage more rigorous methods
to translate and validate imaging methods. For example, this ini-
tiative encourages the submission of investigator-initiated R01
applications to develop databases and quantitative imaging
methods for targeted cancer problems with an option to be
linked to any of NCI research networks as previously described
above [16].
This issue of Translational Oncology includes four reports [17–20]
that reflect the progress made during the last 18 months by the RIDER
resource. NCI supported a total of six contracts during 2008 for data
collection (five academic sites) that have included phantom mea-
surements and/or patient data collections from clinical trials or other
investigations supported by the academic institutions. Each of these
academic investigators agreed to share their data as a public resource
including their results of analysis. This resource will thus serve the im-
aging research community by permitting comparative analysis of data
sets by other investigators. This public resource and all related docu-
mentation on the data collections are Web-accessible and can be found
at the National Cancer Imaging Archive. The National Cancer Imaging
Archive is now referred to as the National Biomedical Imaging Archive
(NBIA) because it is archiving data from several National Institutes of
Health (NIH) institutes and other agencies of the federal government
[12]. It includes repeat and longitudinal data using either quality assur-
ance phantoms or patient studies. Imaging modalities include x-ray
computed tomography (CT), positron emission tomography (PET)–
CT, dynamic contrast-enhanced (DCE)–magnetic resonance imaging
(MRI), and diffusion-weighted (DW)MRI, and different organ systems
(lung, breast, neuro) are represented in the database. In addition several
scientific societies such as the Society of Nuclear Medicine, American
Association of Physicists in Medicine, International Society for Mag-
netic Resonance in Medicine (ISMRM), and Radiological Society of
North America (RSNA) have agreed to participate in these efforts.
The FDA Center for Devices and Radiological Health with partial
contract support from NCI and the National Institute of Biomedical
Imaging and Bioengineering, has generated a wide range of image data
collections using an x-ray CT lung phantom with repeat and longitu-
dinal studies using a array of simulated lung nodules and should serve
as a resource to evaluate software tools and Response Criteria for Solid
Tumors measurements, where spatial ground truth is known. In addi-
tion, National Institute of Standards and Technology (NIST) has initi-
ated strategic plans to address standards for biomedical research where
imaging is one of the areas that are being addressed. Two key initiatives
have been initiated: a Ge-68 reference standard for longitudinal PET
quantitative imaging studies [21] and a Biochange Project that provides
a means to benchmark the performance of software tools for measure-
ment of change over time during the course of therapy [22].
Each of the four publications in this issue of Translational Oncology
was submitted specifically as a consensus publication, with scientific
input from all investigators involved in the NCI RIDER initiative.
The goal of this work was to explore the different sources of uncertainty,
identify those can be minimized, and establish a very practical means to
characterize measurement uncertainty. The first report by Meyer et al.
[17] provides a solid scientific rationale and research strategy for the
design of the data collections that address a means to estimate mea-
surement uncertainty for both idealized phantom measurements and
patient data. This publication should serve as an excellent reference
resource for investigators developing reference databases resources or
clinical trial protocols, where physical measurement uncertainty is im-
portant to characterize. The next three publications by McNitt-Gray
et al. [18], Kinahan et al. [19], and Jackson et al. [20] address the spe-
cific measurements and methods for analysis for three modalities that
are emerging for imaging as a biomarker, namely x-ray CT, PET-CT,
and DCE and DWMRI. They clearly pose different challenges that are
modality and imaging protocol specific and likely require differing com-
plexities of associated modeling and image analysis tools. The intent of
these publications was to provide an initial level of consensus for how
to characterize the physical measurement uncertainty for these imaging
methods in terms of quantity assurance and data analysis. This pre-
liminary work by all should serve to help develop a consensus for how
to physically characterize the quality assurance and quantitative imag-
ing methods that will be explored in the NCI-planned QIN [14] and
potentially other clinical trial networks. As a related but parallel effort,
Barnhart and Barboriak [23] have reviewed how statistical analysis
of repeatability derived from repeat patient data sets can be used to
interpret parameter changes in individual patients, to evaluate inter-
changeability of devices, and to power studies to more precisely deter-
mine repeatability.
NCI is currently supporting two new contracts for 2009. For exam-
ple, in addition to harmonization of methods for data analysis, there is
a critical need to explore how to improve harmonization of data
collection across different commercial imaging platforms. An excellent
example is DWMRI, where there is a diverse array of different vendor-
supported methods for data acquisition and analysis. This emerging
method is proving to be very valuable for providing early indication
of response to therapy. NCI organized a workshop on this topic at
the ISMRM meeting in 2008 that resulted in a comprehensive con-
sensus report [24]. A second workshop was held at the ISMRM in
2009, where the imaging industry agreed to explore strategies to opti-
mize and harmonize DWMRI data collection, with a goal of reducing
platform dependence on DWmeasurements. This is the first reported
effort for harmonizing data collection across commercial platforms
for imaging as applied to oncology. NCI expects that under the QIN
initiative that additional efforts will be explored to harmonize data col-
lection for other modalities and imaging protocols such as PET-CT,
DCE MRI, and MR spectroscopy. The second contract addresses the
collection of PET-CT phantom data across multiple sites that are
representative of the environment of clinical trials sites. The goals are
to optimize data analysis methods that reflect time-related drift in
instrument performance for both the dose calibrator and PET sys-
tems across all sites, using the NIST reference standard for Ge-68.
This work is being performed in consultation with the Society of
Nuclear Medicine and American Association of Physicists in Medicine,
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and the American College of Radiology Imaging Network (ACRIN)
PET Core Laboratory.
In summary, the initial attempts for data and results sharing under
the RIDER project, as reflected the publications reported in this issue,
has stimulated the research community to volunteer to create similar
resources, several of which are archived on NBIA. The scale of this in-
terest was initially evident in 2006 by the attendance of all imaging
stake holders at an interagency workshop held at NIST that addressed
the physical measurement uncertainty for imaging as a biomarker [6].
The leadership of all the major imaging society attended this workshop
and lead to a decision by the RSNA to take the initiative to organize all
stakeholders in this area including industry to consider the develop-
ment of physical imaging standards. As a result of this and several other
NIH workshops and workshops organized by several imaging societies
on the topic of imaging as a biomarker, the RSNA in 2008 formulated
the Quantitative Imaging Biomarker Alliance (QIBA) [25]. QIBA has
already organized a series of meetings to engage academia and the imag-
ing and pharmaceutical industries to consider quantitative imaging
standards for oncology and other disease entities. One example of the
outcome of QIBA efforts has resulted in a recent publication on the
potential role of Volumetric CT as a biomarker for therapy response
that has included participation of industry stakeholders in the consen-
sus process [25]. Because the principal government agency responsible
for standard development and establishment is NIST, it would be
appropriate for NIST to play a key role in leading a consortium of
imaging societies that will address standards for biomedical measure-
ments. This activity should be informed by NIH-supported research
in the evaluation of biomarkers and validation of other measurements.
As a result of the broad engagement of all major stakeholders, imaging
is now poised to one of the first biomarker methods that may be (physi-
cally) standardized within a reasonable time line, both nationally and
ideally internationally.
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